Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRYZ-T102 TCR-T cells in AFP positive hepatocellular carcinoma
NCT06515314Phase 1Recruiting
- Sponsor
- Ruiliyuan Biotechnology
- Start
- Oct 2024
- Primary completion
- Aug 2026
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AFP specific T cell receptor T cells in hepatocellular carcinoma (HCC), sponsored by Ruiliyuan Biotechnology. Primary endpoints: Adverse Events at 2 years and Dose-Limiting Toxicity at 2 years. Started Oct 2024; status: recruiting.
02
Drugs
AFP specific T cell receptor T cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06515314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06515314.